Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saved in:
| Title: | Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. |
|---|---|
| Authors: | Marret G; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Isambert N; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France., Rezai K; Radio-Pharmacology Department, Institut Curie, Saint Cloud, France., Gal J; Epidemiology and Biostatistics Unit, Centre Antoine Lacassagne, Nice, France., Saada-Bouzid E; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte D'Azur, Nice, France., Rolland F; Department of Medical Oncology, Institut René Gauducheau, Saint Herblain, France., Chausson M; UNICANCER, Paris, France., Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Alt M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Klijanienko J; Department of Pathology, Institut Curie, Paris, France., Vansteene D; Department of Medical Oncology, Institut René Gauducheau, Saint Herblain, France., Guigay J; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte D'Azur, Nice, France., Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France., Bièche I; Department of Genetics, Institut Curie, Paris Descartes University, Paris, France.; INSERM U1016, Cochin Institute, Paris, France., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France. christophe.letourneau@curie.fr.; INSERM U900, Institut Curie, Mines Paris Tech, Saint-Cloud, France. christophe.letourneau@curie.fr.; Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr. |
| Corporate Authors: | UNICANCER Head, Neck Group |
| Source: | Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1641-1648. Date of Electronic Publication: 2021 Jul 28. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
